Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Srivarshini Kanukollu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Antiemetics, Neoplasms, Hypersensitivity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
NK‐1 receptor antagonists (NK1‐RA) are key agents for chemotherapy‐induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy. Current pediatric practice guidelines recommend the use of intravenous fosaprepitant or oral aprepitant. However, there are reports of hypersensitivity reactions with fosaprepitant due to polysorbate 80. Intravenous aprepitant does not contain polysorbate 80, but its use in pediatric patients has not been described. In this retrospective, single‐center study, 106 pediatric patients received either fosaprepitant or intravenous aprepitant as part of their antiemetic regimen. Intravenous aprepitant was well tolerated and did not lead to any instances of hypersensitivity reactions requiring discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Srivarshini Kanukollu, Jessica A Lavery
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Kanukollu, S., Spatz, K., Lavery, J. A., Bender, J. G., Mauguen, A., & Mathew, S. (2024). Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30882
Vancouver
Kanukollu S, Spatz K, Lavery JA, Bender JG, Mauguen A, Mathew S. Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30882
BibTeX
@article{Kanukollu2024,
author = {Kanukollu, Srivarshini and Spatz, Krisoula and Lavery, Jessica A and Bender, Julia Glade and Mauguen, Audrey and Mathew, Sherry},
title = {Safety and tolerability of intravenous aprepitant and fosaprepitant in children with cancer: A retrospective, single‐center review},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30882}
}
EUVIMED